Pediatric Hematology and Oncology Unit, Department of Pediatrics, Bolzano Hospital, Bolzano, Italy.
Nuclear Medicine Unit, Department of Medicine - DIMED, University Hospital of Padova, Padova, Italy.
Eur J Cancer. 2021 Sep;155:155-162. doi: 10.1016/j.ejca.2021.07.006. Epub 2021 Aug 9.
Initial staging of rhabdomyosarcoma is crucial for prognosis and to tailor the treatment. The standard radiology workup (SRW) includes magnetic resonance imaging, chest computed tomography (CT) and bone scintigraphy, but 18 Fluorine-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (F-FDG-PET/CT (PET-CT)) use is increasing. The aim of this study was to evaluate the impact of PET-CT in the initial staging of patients with metastatic rhabdomyosarcoma enrolled in the European protocol MTS2008.
Two authors retrospectively reviewed the SRW and PET-CT reports comparing the number and sites of metastases detected. For bone marrow involvement, PET-CT and bone marrow aspirates/biopsies were compared.
Among 263 metastatic patients enrolled from October 2008 to December 2016, 121 had PET-CT performed at diagnosis, and for 118 of 121 patients, both PET-CT and radiological reports were available for review. PET-CT showed higher sensitivity than SRW in the ability to detect locoregional (96.2% versus 78.5%, P value = 0.0013) and distant lymph node involvement (94.8% versus 79.3%, P value = 0.0242), but sensitivity was lower for intrathoracic sites (lung 79.6% versus 100%, P value = 0.0025). For bone metastasis, PET-CT was more sensitive than bone scintigraphy (96.4% versus 67.9%, P value = 0.0116). The PET-CT sensitivity and specificity to detect marrow involvement were 91.8% and 93.8%, respectively. The mean number of metastatic sites was 1.94 (range 0-5) with PET-CT and 1.72 (range 0-5) with SRW. In four patients (3.4%), PET-CT changed the staging from localised to metastatic disease.
PET can identify metastatic disease not evident on SRW in a small number of patients. This is because of its higher ability to recognise lymph node and bone involvement. Chest CT remains essential to detect lesions in intrathoracic sites, which can be performed in a one stop-shot routine examination or on a dedicated chest CT scan. PET-CT could replace bone scintigraphy to study bone involvement.
横纹肌肉瘤的初始分期对于预后和治疗方案的制定至关重要。标准影像学检查(SRW)包括磁共振成像(MRI)、胸部计算机断层扫描(CT)和骨闪烁扫描,但氟-18 氟代脱氧葡萄糖(FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)(F-FDG-PET/CT(PET-CT))的应用正在增加。本研究旨在评估 PET-CT 在欧洲方案 MTS2008 纳入的转移性横纹肌肉瘤患者初始分期中的作用。
两名作者回顾性比较了转移性患者的 SRW 和 PET-CT 报告,以评估转移部位和数量。对于骨髓受累,比较了 PET-CT 和骨髓抽吸/活检。
2008 年 10 月至 2016 年 12 月期间,共纳入 263 例转移性患者,其中 121 例在诊断时进行了 PET-CT 检查,121 例中有 118 例的 PET-CT 和放射学报告可供审查。与 SRW 相比,PET-CT 在检测局部区域(96.2%对 78.5%,P 值=0.0013)和远处淋巴结受累(94.8%对 79.3%,P 值=0.0242)方面具有更高的敏感性,但在胸内部位的敏感性较低(肺 79.6%对 100%,P 值=0.0025)。对于骨转移,PET-CT 比骨闪烁扫描更敏感(96.4%对 67.9%,P 值=0.0116)。PET-CT 检测骨髓受累的敏感性和特异性分别为 91.8%和 93.8%。PET-CT 检测到的转移部位平均数量为 1.94(范围 0-5),SRW 为 1.72(范围 0-5)。在 4 例患者(3.4%)中,PET-CT 将疾病分期从局限性改为转移性。
在少数患者中,PET 可以识别出 SRW 上未显示的转移性疾病。这是因为它能更好地识别淋巴结和骨骼受累。胸部 CT 仍然是检测胸内病变所必需的,可以在一次检查中进行或进行专门的胸部 CT 扫描。PET-CT 可以替代骨闪烁扫描来研究骨骼受累情况。